5.Diagnosed of Secondary Hyperparathyroidism (SHPT), with averaged iPTH ≥400 pg/ml14 days prior to screening;
6.Receiving active vitamin D sterols must have had no more than a maximum dose change of 50% within the 1 month prior to screening, remain stable;
7.Subject receiving calcium supplements, or phosphate binders must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening, remain stable;
You may not be if
1.The subjects underwent parathyroidectomy within 6 months prior to screening, or plan to undergo parathyroidectomy or ablation or radiation during the study;
2.Gastrointestinal bleeding or peptic ulcer medical history within 6 months prior to screening;
3.The body mass index of the subjects was less than 18kg/m2 or greater than 35 kg/m2;
4.Subjects with severe uncontrolled hypertension, defined as systolic blood pressure\>180 mmHg and/or diastolic blood pressure\>110 mmHg(Except for transient blood pressure abnormalities seen during dialysis), despite optimal drug treatment prior to enrollment;
5.History of epileptic seizures or ongoing epilepsy related treatment within 1 year prior to screening;
6.Subjects with a history of malignant tumors within the past 5 years prior to screening;
7.Subjects are allergic or intolerant to any component of the investigational drug or Etelcalcetide
Clareo Health | MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease
